Cited by 501Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Xu, Jianming, Zhang, Yun, Jia, Ru, Yue, Chunyan, Chang, Lianpeng, Liu, Rongrui, Zhang, Gairong, Zhao, Chuanhua, Zhang, Yaoyue, Chen, Chunxia, Wang, Yan, Yi, Xin, Hu, Zhiyuan, Zou, Jianjun, Wang, Quanren·2019·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-18-2484

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: This study assessed the safety and efficacy of SHR-1210 (anti-PD-1 antibody) and apatinib (VEGFR2 inhibitor) as combination therapy in patients with advanced hepatocellular carcinoma (HCC), gastric, or esophagogastric junction cancer (GC/EGJC). Patients and Methods: This was an open-label, dose-escalation (phase Ia) and expansion study (phase Ib). In phase Ia, patients (n = 15) received SHR-1210 200 mg every 2 weeks and apatinib 125–500 mg once daily until unacceptable toxicity or disease progression. In phase Ib, patients (n = 28) received apatinib at the phase Ia–identified recommended phase II dose (RP2D) plus SHR-1210. The primary objectives were safety and tolerability and RP2D determination. Results: At data cutoff, 43 patients were enrolled. In phase Ia, four dose-limiting toxicity events were observed (26.7%): one grade 3 lipase elevation (6.7%) in the apatinib 250 mg cohort and three grade 3 pneumonitis events (20%) in the apatinib 500 mg cohort. The maximum tolerated RP2D for apatinib was 250 mg. Of the 33 patients treated with the R2PD combination, 20 (60.6%) experienced a grade ≥3 treatment-related adverse event; adverse events in ≥10% of patients were hypertension (15.2%) and increased aspartate aminotransferase (15.2%). The objective response rate in 39 evaluable patients was 30.8% (95% CI: 17.0%–47.6%). Eight of 16 evaluable HCC patients achieved a partial response (50.0%, 95% CI: 24.7%–75.4%). Conclusions: SHR-1210 and apatinib combination therapy demonstrated manageable toxicity in patients with HCC and GC/EGJC at recommended single-agent doses of both drugs. The RP2D for apatinib as combination therapy was 250 mg, which showed encouraging clinical activity in patients with advanced HCC.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-2484

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,725
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756

Show all 46 references

Sorted by citations

Items 301–400 of 501

Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
Chen, J., Feng, L., Sheng, Q., & Li, L. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/8720679 · Cited by 8
Retracted
Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer
Lv, W., Cheng, K., Li, X., Feng, L., Li, H., Li, J., Chang, C., & Cao, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.759652 · Cited by 8
Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer
Sun, J., Yao, N., Lü, P., & Wang, Y. (2022) · Cellular and Molecular Biology · doi:10.14715/cmb/2021.67.5.48 · Cited by 8
Self-citation
Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy
Zhang, T., Zhang, C., Fu, Z., & Gao, Q. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091768 · Cited by 8
Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases
Xu, J., Liu, X., Yang, S., & Shi, Y. (2019) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504019x15707896762251 · Cited by 8
Self-citation
TATI modality: A new perspective on the treatment of advanced hepatocellular carcinoma
Liang, P., Ye, X., & Li, X. (2020) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_850_20 · Cited by 8
Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Zhao, J., He, M., Li, J., Li, D., Zhao, Y., Li, X., Zhang, X., Chen, X., Liu, Y., & Zhao, L. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2021.0086 · Cited by 8
A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient
Lin, Y., Lin, Y., Zhong, X., Chen, Q., Tang, S., & Chen, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1280208 · Cited by 7
A CT-Based Clinical-Radiomics Nomogram for Predicting the Overall Survival to TACE Combined with Camrelizumab and Apatinib in Patients with Advanced Hepatocellular Carcinoma
Ding, G., & Li, K. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.10.052 · Cited by 7
Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study
Zhang, F., Wang, Y., Li, S.-P., Zhao, B. R., Huang, N., Song, R., Meng, F., Feng, Z.-W., Zhang, S., Song, H., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02202-y · Cited by 7
Self-citation
PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy
Gong, C., You, S., Zhang, Q., Yang, Z., Bi, X., Zhao, H., Sun, Y., Zhou, J., Rong, W., Zhao, J., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013381 · Cited by 8
Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report
Qin, L., Shen, J., Yang, Y., & Zou, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692480 · Cited by 7
Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer
Liu, H., Li, Y., Yao, Y., Chen, K., & Gan, J. (2022) · Disease Markers · doi:10.1155/2022/6971717 · Cited by 7
New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations
Edeline, J., Meyer, T., Blanc, J., & Raoul, J. (2022) · Cancers · doi:10.3390/cancers14235868 · Cited by 9
Light-enhanced VEGF121/rGel induce immunogenic cell death and increase the antitumor activity of αCTLA4 treatment
Longva, A. S., Berg, K., & Weyergang, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1278000 · Cited by 7
The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma
Nakayama, I., & Shitara, K. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2395921 · Cited by 7
Association between reactive cutaneous capillary endothelial proliferation and the efficacy of camrelizumab in esophageal cancer: a retrospective cohort study
Qiu, Y., Su, G., Zhang, L., Fan, H., Zhao, H., Wang, C., Liu, L., Chen, B., Li, X., & Li, S. (2025) · Journal of Thoracic Disease · doi:10.21037/jtd-2025-366 · Cited by 7
Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature
Liu, L., Liu, Y., Gong, L., Zhang, M., & Wu, W. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1829265 · Cited by 7
The efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic drugs in renal cell carcinomas: a systematic review and meta-analysis
He, Q., Li, J., Zhang, C., Tang, S., & Qinglan, R. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-1975 · Cited by 6
Correlation between Tumor Microenvironment and Immune Subtypes Based on CD8 T Cells Enhancing Personalized Therapy of Gastric Cancer
Wu, J., Xiao, Y., Lu, W., Zhang, Z., Yang, H., Cui, X., Wu, D., & Chen, Y. (2022) · Journal of Oncology · doi:10.1155/2022/8933167 · Cited by 7
Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
Chen, N., Xu, X., & Fan, Y. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231189420 · Cited by 8
Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis
Xian, F., Wu, C., Zhang, G., & Xu, G. (2022) · Medicine · doi:10.1097/md.0000000000031479 · Cited by 7
Self-citation
Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review)
Cheng, M., Zheng, X., Wei, J., & Liu, M. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12285 · Cited by 6
Apatinib Through Activating the RhoA/ROCK Signaling Pathway to Cause Dysfunction of Vascular Smooth Muscle Cells
Wang, W., He, Q., Zhuang, C., Zhang, H., Fan, X., Wang, Q., Qi, M., Sun, R., Li, C., & Yu, J. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-04020-5 · Cited by 6
Self-citation
Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: a systematic review and single-arm meta-analysis
Chen, M., Li, Y., & Cheng, M. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03144-8 · Cited by 6
Apatinib enhances chemosensitivity of ABT ‐199 in diffuse large B‐cell lymphoma
Shi, Y., Ye, J., Shen, H., Xu, Y., Wan, R., Ye, X., Jin, J., & Xie, W. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13309 · Cited by 7
Complete remission of alpha-fetoprotein-producing gastric cancer by combined tislelizumab-apatinib treatment of a patient with proficient mismatch repair: a case report
Xiang, J., Gong, W., Wang, C., Sun, P., & Liu, A. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02751-7 · Cited by 6
Immune checkpoint inhibitors are effective in the treatment of Epstein-Barr virus-associated gastric cancer: A case report
An, G., He, X., Bai, J., & Wang, J. (2023) · Medicine · doi:10.1097/md.0000000000033377 · Cited by 6
Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Ding, Q., Liu, Y., Ju, H., Song, H., Xiao, Y., Liu, X., Ren, G., & Wei, D. (2020) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.25919 · Cited by 6
The potential combinational immunotherapiesfor treatment of hepatocellular carcinoma
Kang, S., Bai, X., Chen, S., Song, Y., & Liu, L. (2019) · Journal of interventional medicine · doi:10.1016/j.jimed.2019.09.006 · Cited by 6
A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report
Chen, Y., Zhang, H., Shi, J., & Wang, T. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s279004 · Cited by 6
Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review
Li, J., Liang, H., He, J., Sui, X., & Qin, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639168 · Cited by 6
Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report
Li, X., Gu, X., Xu, J., Chen, L., Li, H., Meng, D., Bai, H., Yang, J., & Qian, J. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s310421 · Cited by 6
Self-citation
Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review
Zhou, W., Huang, J., He, Q., Luo, Q., Zhang, X., Tao, X., Dong, H., & Tu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764352 · Cited by 6
Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
Yao-qiang, W., Han, L., You, X., Guo, T., Sun, T., Xu, H. Y., & Fu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.764923 · Cited by 7
Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors
Shen, J., Yan, J., Du, J., Li, X., Wei, J., Liu, Q., Yong, H., Wang, X., Chang, X., Ding, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133689 · Cited by 6
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions
Balsano, R., Pino, M., Bocchero, E., Valenzi, E., Pressiani, T., Bozzarelli, S., & Rimassa, L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2557625 · Cited by 5
Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports
Zhang, Z., & Zheng, C.-Q. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i29.10550 · Cited by 5
Clinical value of identifying genes that inhibit hepatocellular carcinomas
Testa, U., Pelosi, E., & Castelli, G. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2154658 · Cited by 5
Prognostic Prediction Value and Biological Functions of Non-Apoptotic Regulated Cell Death Genes in Lung Adenocarcinoma
Li, H.-L., Wang, J., Dai, H.-W., Liu, J.-J., Liu, Z., Zou, M., Zhang, L., & Wang, W. (2023) · Chinese Medical Sciences Journal · doi:10.24920/004222 · Cited by 5
Immunotherapeutic strategy in the management of gastric cancer: molecular profiles, current practice, and ongoing trials
Lu, M., Wu, Y., Zhang, Y., Yu, Y., Wang, S., & Su, X. (2023) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-023-00192-1 · Cited by 5
Self-citation
Sequencing Systemic Therapy in Hepatocellular Carcinoma
Ponvilawan, B., & Roth, M. T. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01135-7 · Cited by 5
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study
Ren, S., Xiong, A., Yu, J. H., Wang, X., Han, B., Pan, Y., Zhao, J., Cheng, Y., Hu, S., Liu, T., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03715-4 · Cited by 7
Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies
Dong, D., Xue, Y., Liu, H., Xu, J., Guo, J., Guo, W., Li, X., Wang, F., Zhang, D., Liu, K., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.01.007 · Cited by 6
Self-citation
Immune checkpoint inhibitor combined with anti-angiogenesis agent inhibits metastasis of advanced adenoid cystic carcinoma of the tongue base to the lung: a case report
Zhang, K., Wang, H., Fang, J., & Xu, Q. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3426 · Cited by 5
[Anti-angiogenesis in Lung Cancer: Current Situation, Progress and Confusion].
Zhou, J., & Chen, J. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.16 · Cited by 5
Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study
Li, L., Chen, W.-C., & Wu, G. (2022) · Disease Markers · doi:10.1155/2022/4322404 · Cited by 5
Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
Li, Z., Chen, Q., Zhang, W., Si, G., Li, J., Jiao, D., & Han, X. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/5565793 · Cited by 5
Therapeutic Interaction of Apatinib and Chidamide in T-Cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis
Zhong, M., Lin, F., Jiang, Y., Pan, G., Tan, J., Zhou, H., Lai, Q., Chen, Q., Deng, M., Zha, J., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11100977 · Cited by 5
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial
Peng, Z. S., Zhang, Y., Xu, H., Yang, Y., Yang, M., Zhang, M., Cheng, Y., Chen, X., Pan, Y., Wang, F., et al. (2026) · BMJ · doi:10.1136/bmj-2025-086115 · Cited by 4
Self-citation
A real-world analysis of second-line treatment option, gemcitabine plus anlotinib and anti-PD1, in advanced pancreatic cancer
Fan, M., Ma, Y., Deng, G., Si, H., Jia, R., Wang, Z., & Dai, G. (2024) · Pancreatology · doi:10.1016/j.pan.2024.03.017 · Cited by 4
Self-citation
Stem cell-like circulating tumor cells identified by Pep@MNP and their clinical significance in pancreatic cancer metastasis
Chu, X., Zhong, X., Zang, S., Wang, M., Li, P., Ma, Y., Tian, X., Yang, Y., Wang, C., & Yang, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1327280 · Cited by 4
The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
Wang, K., Li, B., Li, M., Li, S., Yang, H. J., & Yuan, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.568477 · Cited by 4
Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial)
Zhou, C., Shangguan, C., Shi, M., Xi, W., Wu, J., Yang, H. J., Guo, L., Cai, Q., Shi, Y. X., Liu, J., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-1579 · Cited by 4
Camrelizumab as adjuvant therapy in urothelial carcinomas after radical surgery in people living with HIV
Wu, M., Pang, Y., Zheng, X., & Zhao, J. (2023) · International Journal of STD & AIDS · doi:10.1177/09564624231173179 · Cited by 4
Significant response to transarterial chemoembolization combined with PD-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma: A case report and literature review
Zhang, H., Han, C., Zheng, X., Zhao, W., Liu, Y., & Ye, X. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1697_22 · Cited by 4
Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
Zhou, W., Huang, J., Lü, X., Hu, D., Hong, X., Wang, F., Lv, P.-H., & Zhu, X. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s494520 · Cited by 4
Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study
Gan, B., Wu, L., Zhou, S., Chen, Z., Wu, F., Xu, L., Chen, Z., Ma, H., He, P., Fang, D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1476146 · Cited by 5
Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy
Tao, C., Zhang, P., Zhou, L., Hu, Q., & Chen, X. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-1773 · Cited by 4
Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis
Wang, J., Lin, J., Wang, R., Tong, T., & Zhao, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-12340-4 · Cited by 4
Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study
Li, S., Yu, Z., Liu, H., Li, S., Wang, M., Ning, F., & Tian, L. (2024) · Cancer Medicine · doi:10.1002/cam4.7349 · Cited by 3
Clinical advances and challenges of anti-angiogenic targeted therapy in gastric cancer
Wu, Z., Ni, J., & Xu, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1654300 · Cited by 3
Prognostic value of CD28⁻CD57⁺CD8⁺ T cells for early immunotherapy response in hepatocellular carcinoma: a prospective observational study
Zhou, S., Liu, Z., Guo, J., Ma, K., Xu, X., Zhang, B., Sun, C. H., Zhao, F., & Liu, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-29426-z · Cited by 3
Exploratory biomarker findings from regorafenib plus toripalimab in patients with refractory metastatic colorectal cancer (REGOTORI study)
Yao, Y.-C., He, M.-M., Wang, M., Mo, Y., Zhao, Q., Jin, Y., Hou, T., Chen, Y., & Wang, F. (2026) · Gastroenterology report · doi:10.1093/gastro/goag009 · Cited by 3
Reactive cutaneous capillary endothelial proliferations of the eyelids induced by camrelizumab: A case report
Zhou, X., Yan, X., & Wu, Y. F. (2024) · Biomedical Reports · doi:10.3892/br.2024.1743 · Cited by 3
Tumor cell stemness in gastrointestinal cancer: regulation and targeted therapy
Yang, K., & Yi, T. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1297611 · Cited by 5
Immune checkpoint inhibitors combined with paclitaxel-based chemotherapy versus chemotherapy alone as first-line treatment in HER2-negative advanced gastric cancer: result of a multicenter retrospective study
Fang, Y., Zhao, Y., Yu, X., Liu, S., Tao, G., Zhong, H., Xiang, H., Yang, Y., & Shi, Z. Q. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-814 · Cited by 3
RETRACTED: Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score–Matched Study of 1,008 Patients
Zhang, H., Xu, J., Meng, H., & Shen, L. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.09.005 · Cited by 3
Self-citation
Retracted
Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma
Zheng, L., Tao, C., Tao, Z., Zhang, K., Wu, A., Wu, J., & Rong, W. (2021) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v13.i10.1136 · Cited by 3
Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma
Wang, H., Zhu, X., Zhao, Y., Dong, D., Li, L., Cai, Y., Li, Y., & Wang, W. (2022) · BMC Cancer · doi:10.1186/s12885-022-09819-3 · Cited by 3
A combination of anti-PD-1 therapy and apatinib successfully treated a patient with EGFR mutation-negative advanced lung adenocarcinoma: A case report
Wang, J., Li, S., Zhang, L., & Zhang, X. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1710_21 · Cited by 3
Camrelizumab combined with apatinib in the treatment of patients with hepatocellular carcinoma: a real-world assessment
Chen, D., Chen, X., Xu, L., Wang, Y., Zhu, L., & Kang, M. (2023) · Neoplasma · doi:10.4149/neo_2023_230413n206 · Cited by 3
Self-citation
Camrelizumab and apatinib combined with chemotherapy in perioperative effective therapy for advanced gastric carcinoma with peritoneal metastasis: a case report
Song, L., Fang, X., Jiang, P., Li, Y., Li, X., Xu, X., Liang, Y., Li, C., & Zheng, Y. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-741 · Cited by 3
LRRC25 Is a Potential Biomarker for Predicting Immunotherapy Response in Patients with Gastric Cancer
Yang, Z., Yu, B., Hu, J., Jiang, L., & Jian, M. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08882-7 · Cited by 3
Immune Checkpoint Inhibitor-Based Systemic Therapy Shows Remarkable Curative Effect in a Hepatocellular Carcinoma Patient With Intractable Postoperative Recurrence and Metastases: A Case Report and Literature Review
He, X., Peng, Y., Zhou, Z., & Li, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.784224 · Cited by 3
Immunotherapy in hepatocellular carcinoma: Combination strategies
Jordan, A. C., & Wu, J. J. (2020) · World Journal of Meta-Analysis · doi:10.13105/wjma.v8.i3.190 · Cited by 3
Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?
Catanese, S., & Lordick, F. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4438 · Cited by 3
Combination of anti-angiogenic therapy Apatinib and immune therapy potentiate tumor microenvironment
Gao, C., & Hu, T. (2021) · Trends in Immunotherapy · doi:10.24294/ti.v5.i2.1.1376 · Cited by 2
The application of immunotherapy combined with taxanes in second‑line treatment of advanced HER2 negative gastric cancer
Chen, T., Xu, M., Xu, J., Zhan, X., Zhang, Y., Ying, M., & Wu, M. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2806 · Cited by 2
Self-citation
Research progress on ferroptosis regulation in tumor immunity of hepatocellular carcinoma
Mo, Y., Zou, Z., & Chen, E. (2024) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2024-0117 · Cited by 2
Knowledge mapping and visualization of immune checkpoint inhibitor-related pneumonitis: a bibliometric analysis
Jiang, Y., Xu, M., Xu, S., & Wu, Q. (2025) · Discover Oncology · doi:10.1007/s12672-025-03769-5 · Cited by 2
Efficacy and safety of neoadjuvant camrelizumab and apatinib combined with chemotherapy in stage IIIA (N2) NSCLC: a multi-center, single-arm, phase II trial
Zhao, L., Guo, T., Zhang, Y., Huang, Z. J., Huang, Y., Zhu, L., Chen, X., Zhang, N., Guo, L., Huang, R., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04416-0 · Cited by 2
Self-citation
Treatment of recurrent hepatocellular carcinoma: The current standards and future perspectives
Elsayed, M. O. K. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i11.110735 · Cited by 2
Antiangiogenic agents in the treatment of colorectal, gastric, and gastroesophageal junction adenocarcinoma
Petrioli, R., Miano, S. T., & Martellucci, I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00007-x · Cited by 2
Emerging Treatments for Reactive Cutaneous Capillary Endothelial Proliferation
Liu, Y., Chen, T., Zhang, C., & Pan, W. (2023) · Indian Journal of Dermatology · doi:10.4103/ijd.ijd_505_22 · Cited by 2
Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer
Zhu, J., Yu, Y., Mei, J., Chen, S., Li, J., & Jiang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1278573 · Cited by 2
Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab
Zhang, C., Wang, G., Liu, N., Li, T., Zhu, J., & Hou, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1387465 · Cited by 2
Camrelizumab combined with transcatheter arterial chemoembolization for intermediate or advanced hepatocellular carcinoma: A systematic review and meta-analysis
Liu, L., He, W., & Liu, J. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102465 · Cited by 2
Clinicopathological characteristics of invasive stratified mucinous carcinoma of the cervix and the expression and clinical significance of SLC7A11, SLC3A2 and PD-L1
Lu, C., Zhu, W., Han, X., Du, X., Zhang, H., Yao, Q., Liu, T., & Zhang, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1492498 · Cited by 2
Meta-analysis of the efficiency and safety of neoadjuvant therapy with immune checkpoint inhibitors in resectable hepatocellular carcinoma
Tuersun, A., Mohetaer, M., Hou, G., & Cheng, G. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1511511 · Cited by 4
Pathologically Complete Response to Camrelizumab and Apatinib in Advanced Cervical Cancer with PTEN, PIK3CA, MTOR, and ARID1A Mutations: A Case Report
Liu, Z.-P., Liu, S., He, Z., Ruan, F.-Y., Zhang, D.-X., & Bai, X. (2025) · Case Reports in Oncology · doi:10.1159/000545068 · Cited by 2
Efficacy of radiotherapy combined with targeted therapy and immunotherapy for lymph node metastasis of liver cancer
Yan, H., Xu, J., Li, Z., Li, N., Guo, X., Wu, M., Wang, D., Lin, N., Dong, J., & Xu, X. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06182-1 · Cited by 2
Self-citation
Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy
Zheng, X., & Qian, K. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s520430 · Cited by 2
Immune checkpoint inhibitors combined with targeted therapy for long-term survival in advanced pulmonary squamous cell carcinoma after first-line failure: A case report and literature review
Ke, C., Li, M., Zhang, C., Huang, Q., Deng, Y., & Cheng, J. (2025) · Medicine · doi:10.1097/md.0000000000042724 · Cited by 2
Lipid metabolism associated with efficacy of metronomic capecitabine and camrelizumab in gastrointestinal cancer: an exploratory clinical trial
Zhou, C., Yin, Y., Shangguan, C., Wu, Q., Cai, Q., Xi, W., Guo, L., Jiang, J., Shi, M. Y., Wu, J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04377-4 · Cited by 2
Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas
Lin, F., Guo, C., Yang, Q., Chen, Y., Ke, C., Sai, K., Zhang, J., Jiang, X., Hu, W., Xi, S., et al. (2022) · Glioma · doi:10.4103/glioma.glioma_6_22 · Cited by 2
Immune Checkpoint Inhibitors - New Insights and Recent Progress
Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2
Downstaging Hepatocellular Carcinoma before Transplantation
Lindemann, J. D., Yu, J. S., & Doyle, M. B. M. (2023) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2023.07.001 · Cited by 2
Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Huang, J., & Huang, J. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107435 · Cited by 2
THE EFFECT OF IRRADIATION ON THE INTACT SUPRAVITALLY STAINED MAMMALIAN CELL.
Scanlon, P. W. (1965) · PubMed · Cited by 2

Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial.
Xu, J., Zhang, Y., Jia, R., Wang, Y., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Zou, J., & Wang, Q. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4075 · Cited by 24
Self-citation
Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial.
Zhao, H., Zhao, J., Jiang, L., Bi, X., Qian, H.-G., Du, S., Cai, J., Zhou, J., Li, Z., Liu, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.285 · Cited by 3
Self-citation
724P Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial
Zhao, H.-Y., Du, S., Zhu, Z., Jiang, L., Che, X., Qian, H., Song, J., Liu, D., Zhang, Y., Zhang, P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.848 · Cited by 2
Self-citation
Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib
Zhang, Z., Zhou, Y., Hu, K., Li, Z., Wang, Z., & Huang, Y. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.07.005 · Cited by 9
A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Yan, S., Zhang, Y., Bi, X., Zhao, J., Du, S., Huang, Z., Zhang, Y., Liu, D., Li, Z., Zhou, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz438.022
Self-citation

See all

Authors: Xu, J., Zhang, Y., Jia, R., Yue, C., Chang, L., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Chen, C., Wang, Y., Yi, X., Hu, Z., Zou, J., & Wang, Q.
Affiliations: 1Department of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China.
Academy of Military Medical Sciences (CN)
Chinese Academy of Sciences (CN)
3Geneplus-Beijing Institute, Beijing, China.
Jiangsu Hengrui Medicine (China) (CN)
ORCID: Jia, Ru
Yue, Chunyan
Chang, Lianpeng
Liu, Rongrui
Wang, Yan
Yi, Xin
Hu, Zhiyuan
Zou, Jianjun
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2019-01-15
Volume: 25
Issue: 2
Pages: 515-523
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-18-2484
OpenAlex: W2897612290
Cited by: 498
References: 46
Citations by year: 2026: 19 · 2025: 33 · 2024: 67 · 2023: 69 · 2022: 109 · 2021: 91 · 2020: 82 · 2019: 26
FWCI: 18.90
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: Jiangsu Hengrui Medicine Co. Ltd.
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords: pembrolizumab, anti-PD-1, apatinib, VEGFR-2 inhibitors, combination immunotherapy, hepatocellular carcinoma, gastric cancer, gastroesophageal junction cancer, dose-limiting toxicity, pneumonitis, lipase elevation, recommended phase 2 dose, objective response rate
MeSH terms: Antineoplastic Agents, Immunological, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Esophagogastric Junction, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Prognosis, Pyridines, Stomach Neoplasms, Biomarkers, Treatment Outcome, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks